Genomics

Dataset Information

0

Whole-exome sequencing of breast cancer metastasis and corresponding blood samples

ABSTRACT: This study included samples from metastatic breast cancer patients who underwent a biopsy in the context of SAFIR01 (NCT01414933), SAFIR02 (NCT02299999), SHIVA (NCT01771458) and MOSCATO (NCT01566019) prospective trials. These French multicentre trials used high throughput genome analysis on fresh frozen tumor biopsies as a therapeutic decision tool for metastatic cancer patients, with solid cancers (SHIVA, MOSCATO) or specifically with breast cancer (SAFIR01, SAFIR02). All patients gave their informed consent for translational research and genetic analyses of their somatic DNA. Overall, whole-exome sequencing for a total of 216 pairs of metastatic tumor and unmutated DNA derived from corresponding blood samples was performed using Illumina technology. The results of the analysis of the mutational profile of metastatic breast cancer was reported in Lefebvre et al. (PMID:28027327).

PROVIDER: EGAS00001001695 | EGA |

REPOSITORIES: EGA

Json Xml
altmetric image

Publications

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.

Lefebvre Celine C   Bachelot Thomas T   Filleron Thomas T   Pedrero Marion M   Campone Mario M   Soria Jean-Charles JC   Massard Christophe C   Lévy Christelle C   Arnedos Monica M   Lacroix-Triki Magali M   Garrabey Julie J   Boursin Yannick Y   Deloger Marc M   Fu Yu Y   Commo Frédéric F   Scott Véronique V   Lacroix Ludovic L   Dieci Maria Vittoria MV   Kamal Maud M   Diéras Véronique V   Gonçalves Anthony A   Ferrerro Jean-Marc JM   Romieu Gilles G   Vanlemmens Laurence L   Mouret Reynier Marie-Ange MA   Théry Jean-Christophe JC   Le Du Fanny F   Guiu Séverine S   Dalenc Florence F   Clapisson Gilles G   Bonnefoi Hervé H   Jimenez Marta M   Le Tourneau Christophe C   André Fabrice F  

PLoS medicine 20161227 12

<h4>Background</h4>Major advances have been achieved in the characterization of early breast cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes, yet limited information is available on the genomic profile of this disease. This study aims to decipher mutational profiles of mBC using next-generation sequencing.<h4>Methods and findings</h4>Whole-exome sequencing was performed on 216 tumor-blood pairs from mBC patients who underwent a biopsy in the context  ...[more]

Similar Datasets

Genomics ena-DATASET-IGR-28-10-2016-14:22:46:181-287 - samples
| EGAD00001002747 | EGA
Transcriptomics Identification of Jun loss that promotes resistance to HDAC inhibitor Entinostat through Myc signaling in Luminal breast cancer [cell line]
2018-12-10 | GSE118741 | GEO
Genomics Identification of Jun loss that promotes resistance to HDAC inhibitor Entinostat through Myc signaling in Luminal breast cancer [CGH]
2018-12-10 | GSE118743 | GEO
Transcriptomics Identification of Jun loss that promotes resistance to HDAC inhibitor Entinostat through Myc signaling in Luminal breast cancer (expression)
2018-12-10 | GSE118728 | GEO
Transcriptomics Safir01_Andre_IGR_snp6
2014-04-04 | E-MTAB-2089 | biostudies-arrayexpress
Transcriptomics SAFIR01_FabriceAndre_AGILENT_CGH
2013-04-11 | E-MTAB-2076 | biostudies-arrayexpress
Genomics MiROvaR, a microRNA-based predictor of early relapse for ovarian cancer patients [validation set; OC133]
2016-10-31 | GSE73582 | GEO
Genomics MiROvaR, a microRNA-based predictor of early relapse for ovarian cancer patients [training set; OC179]
2016-10-31 | GSE73581 | GEO
Transcriptomics FinHER trial : Patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer
2016-02-02 | GSE65095 | GEO
Metabolomics Serum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicentre population
2017-03-02 | MTBLS424 | MetaboLights